Results of endoscopic treatment of benign prostatic hyperplasia in patients with metabolic syndrome

Abstract

The present paper is about the research conducted on the patients with metabolic syndrome and its results of endoscopic treatment of benign prostatic hyperplasia in these patients. It is generally accepted that the size and volume of the prostate gland is the main prognostic factor affecting the intraoperative and postoperative outcomes of endoscopic treatment of BPH. However, with the rapid development of endoscopic instruments and surgical techniques, the size of the prostate tends to have a lesser influence on the outcome of endoscopic BPH treatment. Currently, MS is becoming an increasingly common disease, which in most cases predicts a poor prognosis for treatment of patients with LUTS.